We test the hypothesis that endothelial cells adopt an inflammatory phenotype in functionally intact aged human subjects with radiographic evidence of white matter hyperintensity (WMH) suggestive of ...

The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics ...

Although plasma factor H-related protein 5 (FHR5) levels alone were not a significant predictor of ESKD, glomerular FHR5 deposition strongly predicted progression to ESKD.

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer. This is an ASCO Meeting Abstract from the ...

A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...

Shanghai Meiyue Biotech Development Co. Ltd. has synthesized spiro compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

Novartis AG has identified spirocyclic piperidinyl derivatives acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration (AMD), ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), ...

Panel A shows the profile of autoantibodies binding to factor B, C3b, and C3 activation fragments in Patients 1 and 2. I bars denote the standard deviation of three independent tests. As shown in ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor ...